Navigation Links
Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
Date:10/25/2011

al resources available to the company, is no longer tenable.

Background to Regulatory Process

In 2009, AMT filed Glybera for European marketing authorization "under exceptional circumstances". In Europe, this submission process is intended to allow drugs for extremely rare diseases to be approved, realizing that the clinical development package will never contain all the information that would be required for a more common condition.

The dossier was examined by the Committee for Advanced Therapies (CAT) and the CHMP, and in June 2011 both voted against approval of Glybera. AMT appealed the decision based on its interactions with representatives from the CHMP and two new CHMP Rapporteurs were appointed to lead the review process. During the appeal, both rapporteurs, an external scientific advisory group (SAG) consisting of European experts in the areas of gene therapy, lipid metabolism and pancreatitis, was appointed to review and analyze the data and to advise the EMA on its conclusions. The SAG concluded that Glybera should be approved under exceptional circumstances. Subsequently, the CAT performed its own analysis and also voted by a large majority in favor of Glybera marketing authorization. The advice from the SAG, the CAT and both the CHMP Rapporteurs, was provided to the CHMP. However, the CHMP did not change its previous opinion and again voted with the narrowest majority against Glybera marketing authorization. The Company has not yet been informed of the reasons for the CHMP decision.

Operations

Following a careful review of operations and resources needed for development of its remaining pipeline products, AMT management will work in close consultation with the works council to assess the impact of the review on the company's workforce. Management and board believe that for AMT to remain a viable business it needs to reduce the headcount by 50% to 45 full-time employees.

Financials

The measures announced to
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
2. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
3. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
4. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
5. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
6. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
7. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
8. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
9. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
11. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... The discovery 30 years ago of soccer-ball-shaped carbon molecules ... research. Now, there appears to be a new ball ... University and Tsinghua University in China have shown that ... molecular cage similar to a carbon buckyball. It,s the ... a matter of speculationdoes indeed exist. , "This is ...
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... "International Transfection Technology Market - Global Industry Analysis, ... report to their offering. ... to introduce nucleic acids (either DNA or RNA) into ... therapy, mutation of cancer cells and protein metabolism by ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Cayenne ... company specializing in the soft tissue reconstruction segment, ... Anchor System for surgeries involving the shoulder and ... through a novel, inserter-controlled deployment method. The unique ... partial deployment, anchor pull-out, or anchor displacement (also ...
(Date:7/10/2014)... Terascala, the industry leader in HPC ... former vice president of product management for Flexera Software, ... marketing. Terascala’s software when combined with leading compute and ... performance and most reliable solutions for processing big data. ... expansion and broaden its product portfolio. His leadership in ...
Breaking Biology Technology:Researchers discover boron 'buckyball' 2Researchers discover boron 'buckyball' 3International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Terascala Expands Executive Team 2Terascala Expands Executive Team 3
... Madison, Wis. - CDW Corp. , a $6 ... Hills, Ill., has agreed to acquire the stock of Madison-based ... cash. , ,The acquisition, which has been approved by ... the end of October, subject to regulatory approvals and approval ...
... Madison, Wis. - Not everyone is a fan ... most up-to-date technology - fiber to the premises. , ... the pack with trailing-edge technology is pervasive, but ... a different calculation. , ,TDS has introduced its Symmetrical ...
... Stem Cell Bank has announced it will receive human ... , giving it 13 of the 21 stem cell lines ... of the WiCell Research Institute , which houses the ... eventually will have all 21 federally approved lines. , ,"We're ...
Cached Biology Technology:Berbee believes acquisition by CDW will make it a national IT player 2Berbee believes acquisition by CDW will make it a national IT player 3TDS believes faster DSL service will suit small businesses 2Nation's only stem cell bank will receive UC-San Francisco cell line 2
(Date:7/11/2014)... addition to the hippocampus, the marginal division of ... memory. What is the impact degree of substance ... and memory function? Yan Yu and his team, ... found, using immunofluorescence staining, that substance P receptor, ... and striatal marginal division of normal rats. Unilateral ...
(Date:7/11/2014)... type 1 can inhibit voltage-gated calcium channel, ... release. However, some scholars demonstrated that cannabinoid ... influx and increase neurotransmitter release. Dr. Yi ... to Tongji Medical College, Huazhong University of ... voltage-clamp and calcium imaging in cultured trigeminal ...
(Date:7/11/2014)... spider toxins to study the proteins that let nerve ... they have stumbled upon a biological tactic that may ... plagues in a safe and environmentally responsible way. ... lethal for one species and harmless for a closely ... specific pests without harming beneficial species like bees. A ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3
... a human hair to deliver drugs to cells or assist ... of a science fiction movie, but these scenarios may be ... Carbon nanotubes, cylindrically shaped carbon molecules with a diameter of ... of fields, such as biomedical engineering and medical chemistry. ...
... The National Institutes of Health (NIH) has awarded ... University and PATH, a Seattle-based nonprofit organization, to advance ... using patches containing tiny microneedles that dissolve into the ... address key technical issues and advance the microneedle patch ...
... Elsevier ( www.elsevier.com ) , a world-leading ... and services, today announced the launch of SciVerse ... platform that will empower the scientific community to ... search and discovery process through its marketplace and ...
Cached Biology News:Nanotechnology: A dead end for plant cells? 2NIH awards $10 million to advance microneedle patch for flu vaccination 2NIH awards $10 million to advance microneedle patch for flu vaccination 3NIH awards $10 million to advance microneedle patch for flu vaccination 4Elsevier launches SciVerse Applications beta 2Elsevier launches SciVerse Applications beta 3
Biotin-OSu is used to label proteins, immunological agents, DNA and synthetic oligonucleotides. Biotin labeling is detected through enzymatically labeled avidin or streptavidin proteins that conforma...
Cross reactivity to St. Louis encephalitis (MSI-7) is determined by ELISA....
ANTI K. AEROGENES...
casein kinase 2, alpha 1 polypeptide, transcript variant 2, mRNA (cDNA clone MGC:15232 IMAGE:4121882), complete cds...
Biology Products: